Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
183 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diarrhea - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Diarrhea - Pipeline Review, H2 2015', provides an overview of the Diarrhea's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diarrhea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diarrhea Overview 8 Therapeutics Development 9 Pipeline Products for Diarrhea - Overview 9 Pipeline Products for Diarrhea - Comparative Analysis 10 Diarrhea - Therapeutics under Development by Companies 11 Diarrhea - Therapeutics under Investigation by Universities/Institutes 13 Diarrhea - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Diarrhea - Products under Development by Companies 17 Diarrhea - Products under Investigation by Universities/Institutes 20 Diarrhea - Companies Involved in Therapeutics Development 21 A. Menarini Industrie Farmaceutiche Riunite Srl 21 Ache Laboratorios Farmaceuticos S/A 22 Actelion Ltd 23 Aegis Therapeutics, LLC 24 Akthelia pharmaceuticals ehf 25 Allergan Plc 26 Anatara Lifesciences Limited 27 Ardelyx, Inc. 28 Assembly Biosciences, Inc. 29 Chiesi Farmaceutici SpA 30 Chongqing Zhifei Biological Products Co., Ltd. 31 Cosmo Pharmaceuticals S.p.A 32 DesignMedix, Inc. 33 DiscoveryBiomed, Inc. 34 GlaxoSmithKline Plc 35 GP Pharm, S.A. 36 Helsinn Healthcare S.A. 37 Intercept Pharmaceuticals, Inc. 38 Ipsen S.A. 39 Merck & Co., Inc. 40 Mucosis B.V. 41 Nippon Shinyaku Co., Ltd. 42 Novartis AG 43 Pfizer Inc. 44 Prokarium Limited 45 Protagonist Therapeutics Inc. 46 Rebiotix Inc. 47 Sanofi Pasteur SA 48 Scandinavian Biopharma Holding AB 49 Shire Plc 50 Sigmoid Pharma Limited 51 Summit Therapeutics Plc 52 Synthetic Biologics, Inc. 53 Syntiron LLC 54 Diarrhea - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Target 56 Assessment by Mechanism of Action 58 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 ACE-527 - Drug Profile 64 ACE-920 - Drug Profile 66 ACH-04 - Drug Profile 67 AKT-10081 - Drug Profile 68 ASP-7147 - Drug Profile 69 cadazolid - Drug Profile 70 clostridium difficile vaccine - Drug Profile 71 crofelemer DR - Drug Profile 72 diarrhea vaccine - Drug Profile 74 diarrhea vaccine - Drug Profile 75 Drug for Diarrhea - Drug Profile 76 elsiglutide - Drug Profile 77 eluxadoline - Drug Profile 78 Escherichia coli vaccine - Drug Profile 80 ETEC vaccine - Drug Profile 81 Etvax - Drug Profile 82 fidaxomicin - Drug Profile 84 GVXNSD-133 - Drug Profile 87 Helicobacter pylori [Hel-305] (multivalent) vaccine - Drug Profile 88 ibodutant - Drug Profile 89 IMSUTMR-1501 - Drug Profile 90 infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine - Drug Profile 91 iOWH0-32 - Drug Profile 92 lanreotide acetate - Drug Profile 94 MB-101 - Drug Profile 96 obeticholic acid - Drug Profile 97 octreotide acetate - Drug Profile 100 octreotide acetate MAR - Drug Profile 101 Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 102 PF-06425090 - Drug Profile 103 prulifloxacin - Drug Profile 104 PZ-7475 - Drug Profile 106 RBX-2660 - Drug Profile 107 RDX-009 - Drug Profile 109 Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 110 Recombinant Proteins for Infectious Diarrhea - Drug Profile 112 ridinilazole - Drug Profile 113 rifamycin - Drug Profile 115 Small Molecule for Diarrhea - Drug Profile 117 Small Molecule to Block CFTR for Diarrhoea - Drug Profile 118 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 119 Small Molecules for Diarrhea - Drug Profile 120 Small Molecules for Microbial Infections - Drug Profile 121 Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 122 surotomycin - Drug Profile 123 SYN-004 - Drug Profile 124 Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 125 Typhetec - Drug Profile 126 Vaccine for Campylobacter Caused Diarrhea - Drug Profile 127 Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 129 VP-20621 - Drug Profile 130 Yersinia pestis vaccine - Drug Profile 131 Diarrhea - Recent Pipeline Updates 132 Diarrhea - Dormant Projects 166 Diarrhea - Discontinued Products 168 Diarrhea - Product Development Milestones 169 Featured News & Press Releases 169 Appendix 178 Methodology 178 Coverage 178 Secondary Research 178 Primary Research 178 Expert Panel Validation 178 Contact Us 178 Disclaimer 179
List of Tables
Number of Products under Development for Diarrhea, H2 2015 13 Number of Products under Development for Diarrhea - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 15 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Products under Development by Companies, H2 2015 21 Products under Development by Companies, H2 2015 (Contd..1) 22 Products under Development by Companies, H2 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2015 24 Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 25 Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 26 Diarrhea - Pipeline by Actelion Ltd, H2 2015 27 Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2015 28 Diarrhea - Pipeline by Akthelia pharmaceuticals ehf, H2 2015 29 Diarrhea - Pipeline by Allergan Plc, H2 2015 30 Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2015 31 Diarrhea - Pipeline by Ardelyx, Inc., H2 2015 32 Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2015 33 Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H2 2015 34 Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015 35 Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015 36 Diarrhea - Pipeline by DesignMedix, Inc., H2 2015 37 Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2015 38 Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2015 39 Diarrhea - Pipeline by GP Pharm, S.A., H2 2015 40 Diarrhea - Pipeline by Helsinn Healthcare S.A., H2 2015 41 Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 42 Diarrhea - Pipeline by Ipsen S.A., H2 2015 43 Diarrhea - Pipeline by Merck & Co., Inc., H2 2015 44 Diarrhea - Pipeline by Mucosis B.V., H2 2015 45 Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 46 Diarrhea - Pipeline by Novartis AG, H2 2015 47 Diarrhea - Pipeline by Pfizer Inc., H2 2015 48 Diarrhea - Pipeline by Prokarium Limited, H2 2015 49 Diarrhea - Pipeline by Protagonist Therapeutics Inc., H2 2015 50 Diarrhea - Pipeline by Rebiotix Inc., H2 2015 51 Diarrhea - Pipeline by Sanofi Pasteur SA, H2 2015 52 Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2015 53 Diarrhea - Pipeline by Shire Plc, H2 2015 54 Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2015 55 Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2015 56 Diarrhea - Pipeline by Synthetic Biologics, Inc., H2 2015 57 Diarrhea - Pipeline by Syntiron LLC, H2 2015 58 Assessment by Monotherapy Products, H2 2015 59 Number of Products by Stage and Target, H2 2015 61 Number of Products by Stage and Mechanism of Action, H2 2015 63 Number of Products by Stage and Route of Administration, H2 2015 65 Number of Products by Stage and Molecule Type, H2 2015 67 Diarrhea Therapeutics - Recent Pipeline Updates, H2 2015 136 Diarrhea - Dormant Projects, H2 2015 170 Diarrhea - Dormant Projects (Contd..1), H2 2015 171 Diarrhea - Discontinued Products, H2 2015 172
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
